Amir Garakani, MD
- ASSISTANT CLINICAL PROFESSOR | Psychiatry
Dr. Garakani is a former Attending Psychiatrist at Mount Sinai Hospital. He is currently a full-time Attending Psychiatrist at Silver Hill Hospital in New Canaan, CT. He also maintains a small private practice in both New Canaan and New York City. He is Board-Certified in Psychiatry, Forensic Psychiatry and Addiction Medicine. He received his B.A. in Classics (Latin), cum laude, with Distinction in All Subjects, from Cornell University, and his M.D. from the SUNY Upstate Medical University in Syracuse, NY, where he won the AMA Rock Sleyster Scholarship. He completed his residency at the Mount Sinai Medical Center and a research fellowship at the Mood and Anxiety Disorders Program at the Mount Sinai School of Medicine. Dr. Garakani also completed a fellowship in Forensic Psychiatry at New York University Medical Center. He has won several awards including the American Psychiatric Association (APA)/Lilly Resident Research Award, APA – NY County District Branch Resident Research Award, and travel awards from the Anxiety Disorders Association of America and Society of Biological Psychiatry. He also was an APA/GlaxoSmithKline Fellow and a Fellow of the Group of the Advancement of Psychiatry. He has participated in NIMH-funded research and is first or co-author on over 40 peer-reviewed papers and book chapters. He teaches classes to Mount Sinai residents on psychopharmacology and forensic psychiatry and is a supervisor to psychiatry residents and medical students. He previously was elected to the Executive Council of the APA NY County District Branch. He is a Distinguished Fellow of the American Psychiatric Association and a recent Member-Elect of the American College of Psychiatrists.
BA, Cornell University
Fellowship, New York University Medical Center
MD, SUNY Upstate Medical University
Residency, Mount Sinai Medical Center
Garakani A, Shalenberg E, Burstin SC, Weintraub Brendel R, Appel JM. Voluntary psychiatric hospitalization and patient-driven requests for discharge: a statutory review and analysis of implications for the capacity to consent to voluntary hospitalization. Harvard Review of Psychiatry 2014; 22(4): 241-249.
Goldberg JF, Garakani A, Ackerman SH. Clinician- versus self-rated screening for bipolar disorder among inpatients with mood symptoms and substance abuse. J Clin Psychiatry 2012; 73(12): 1525–1530.
Garakani A, Martinez JM, Yehuda R, Gorman JM. Cerebrospinal fluid levels of glutamate and corticotropin releasing hormone in major depression before and after treatment. Journal of Affective Disorders 2013 Apr; 146(2): 262-265.
Krystal JH, Mathew SJ, D’Souza DC, Garakani A, Gunduz-Bruce H, Charney DS. Potential psychiatric applications of metabotropic glutamate receptor glutamate receptor agonists and antagonists. CNS Drugs 2010; 24(8): 669-693.
Garakani A, Buchsbaum MS, Newmark RE, Goodman C, Aaronson CJ, Martinez JM, Torosjan Y, Chu K, Gorman JM. The effect of doxapram on brain imaging in patients with panic disorder. European Neuropsychopharmacology 2007; 17(10): 672-686.
Garakani A, Mathew SJ, Charney DS. Neurobiology of anxiety disorders and implications for treatments. Mount Sinai Journal of Medicine 2006; 73(7): 941-949.
Hirschowitz J, Kolevzon A, Garakani A. The pharmacological treatment of bipolar disorder: the question of modern advances. Harvard review of psychiatry 266-278; 18(5).
Garakani A, Martinez JM, Aaronson CJ, Voustianiouk A, Kaufmann H, Gorman JM. Effect of medication and psychotherapy on heart rate variability in panic disorder. Depression and Anxiety 2009; 26(3): 251-258.